The Roles of Osteopontin In the Pathogenesis of West Nile Encephalitis by Nazneen, Farzana & Bai, Fengwei
The University of Southern Mississippi 
The Aquila Digital Community 
Faculty Publications 
12-1-2020 
The Roles of Osteopontin In the Pathogenesis of West Nile 
Encephalitis 
Farzana Nazneen 
University of Southern Mississippi, arzana.Nazneen@usm.edu 
Fengwei Bai 
University of Southern Mississippi, Fengwei.Bai@usm.edu 
Follow this and additional works at: https://aquila.usm.edu/fac_pubs 
 Part of the Pharmacy and Pharmaceutical Sciences Commons 
Recommended Citation 
Nazneen, F., Bai, F. (2020). The Roles of Osteopontin In the Pathogenesis of West Nile Encephalitis. 
Vaccines, 8(4), 1-12. 
Available at: https://aquila.usm.edu/fac_pubs/19063 
This Article is brought to you for free and open access by The Aquila Digital Community. It has been accepted for 
inclusion in Faculty Publications by an authorized administrator of The Aquila Digital Community. For more 
information, please contact Joshua.Cromwell@usm.edu. 
Review
The Roles of Osteopontin in the Pathogenesis of West
Nile Encephalitis
Farzana Nazneen and Fengwei Bai *
Department of Cell and Molecular Biology, Center for Molecular and Cellular Biosciences,
The University of Southern Mississippi, Hattiesburg, MS 39406, USA; Farzana.Nazneen@usm.edu
* Correspondence: fengwei.bai@usm.edu; Tel.: +1-601-266-4748; Fax: +1-601-266-5797
Received: 14 October 2020; Accepted: 6 December 2020; Published: 9 December 2020


Abstract: Osteopontin (OPN), a multifunctional protein encoded by the secreted phosphoprotein-1
(Spp-1) gene in humans, plays important roles in a variety of physiological conditions, such as
biomineralization, bone remodeling and immune functions. OPN also has significant roles in the
pathogenesis of autoimmune, allergy and inflammatory diseases, as well as bacterial, fungal and
viral infections. West Nile virus (WNV), a mosquito-transmitted flavivirus, is the leading agent
for viral encephalitis in North America. Recent progress has been made in understanding both
the biological functions of OPN and the pathogenesis of WNV. In this review article, we have
summarized the current understanding of the biology of OPN and its vital roles in the pathogenesis
of WNV encephalitis.
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1. Osteopontin
1.1. The Biology of Osteopontin
Osteopontin (OPN) is a negatively charged, acidic and reversibly phosphorylated adhesive
glycoprotein [1]. It is also known as bone sialoprotein-1 (BSP-1), early T-lymphocyte activation-1
(Eta-1), or secreted phosphoprotein-1 (Spp-1) [2]. OPN is a member of the non collagenous protein
group called small integrin binding ligand and N-linked glycoprotein (SIBLING), which also includes
dentin matrix protein-1 (DMP-1), dentin sialophosphoprotein (DSPP), bone sialoprotein-2 (BSP-2) and
matrix extracellular phosphoglycoprotein-1 (MEPE-1) [3,4]. The human OPN gene, Spp-1 is located
on chromosome 4 (4q22.1) at the end of the SIBLING family [5] (Figure 1). The expression of Spp-1 is
regulated by multiple factors including cytokines (e.g., interleukin-1β (IL-1β), IL-6, tumor necrosis
factor-α (TNF-α) and interferon-γ (INF-γ)), platelet-derived growth factor, oxidized low-density
lipoprotein and hormones (e.g., vitamin D, estrogen, angiotensin II and glucocorticoids) [5,6]. OPN is
expressed at high levels in human bone, joints, lung, liver, brain, adipose tissues and body fluids
including blood, urine and milk [7–9]. Although OPN exists both as an immobilized extracellular matrix
(ECM) molecule in mineralized tissues and as a cytokine in body fluids, it is not a typical nonmineralized
ECM [10,11]. OPN is produced by a variety of cell types, such as bone cells (e.g., osteoblasts, osteoclasts
and osteocytes), immune cells (e.g., T cell, B cell, natural killer cell, dendritic cell (DC) and macrophage),
neural, epithelial, fibroblasts, smooth muscle and endothelial cells [5]. OPN acts as a ligand for several
integrins, such as α5β1, α8β1, αvβ1, αvβ3, αIIbβ, αvβ5, αvβ6, α9β4, α9β1 and α4β1 [12–14]. It is also a
ligand for the cluster of differentiation 44 (CD44) molecules specifically for v6 and v7 classes providing
antiapoptotic signals [15,16]. Through the receptor–ligand interactions, OPN exhibits diverse functions
in promoting cancer cell survival, tumor formation, metastasis, granuloma formation, dystrophic
calcification and coronary restenosis [10,16,17].
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Figure 1. Human secreted phosphoprotein-1 (Spp-1) gene genetic location and the post translational 
modification (PTM) sites in osteopontin (OPN) protein. 
OPN gene Spp-1 is located on human chromosome 4 (4q22.1) at the 5’ end of the cluster of the 
five genes, collectively called the “SIBLING family”. OPN messenger RNA (mRNA) can be translated 
into a 314-aa OPN-FL, which is subject to posttranslational modifications (PTMs), such as 
phosphorylation, O-glycosylation, proteolytic processing, tyrosine sulfation, sialylation, thrombotic 
cleavage, polymerization and matrix metalloproteinase (MMP) cleavage. The figure was created in 
Biorender.com. 
1.2. The Different Isoforms of OPN 
Spp-1 consists of seven exons that can produce three different splice variants, i.e., OPN-a, OPN-
b and OPN-c through alternative RNA splicing (Figure 2). While the mRNA of OPN-full-length 
(OPN-FL, OPN-a) contains all of the seven exons, the other splice variants, such as OPN-b and OPN-
c, lack exon-5 or exon-4, respectively [5]. All OPN mRNAs contain exon-2, which acts as the signal 
sequence. The OPN-FL/OPN-a mRNA can be translated into two functionally distinct isoforms, 
secreted OPN-a (sOPN) and intracellular OPN-a (iOPN), respectively. Both OPN-FL isoforms are 
generated from two alternative translation initiation sites, the start codon, adenine uracil guanine 
(AUG) site with the signal sequence or an alternate non-AUG site without the signal sequence [5]. 
The AUG site initiates translation to produce OPN-a (sOPN) isoform consisting of an N-terminal 
signal sequence allowing it to be secreted outside the cell and functioning as a pleiotropic cytokine 
[5]. The alternative non-AUG site initiates translation to generate OPN-a (iOPN), which remains in 
the cytoplasm, premembrane region and nucleus of DCs [18–23]. OPN-b mRNA and OPN-c mRNA 
produce the other two isoforms of sOPNs (OPN-b and OPN-c, respectively) and are translated from 
their mRNAs and secreted out from the cytoplasm [5]. 
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1.2. The Different Isoforms of OPN
Spp-1 consists of seven exons that c n produce three different splice variants, i.e., OPN- , OPN-b
and OPN-c through alternative RNA splicing (Figure 2). While the mRNA of OPN-full-length (OPN-FL,
OPN-a) contains all of the seven exons, the other splice variants, such as OPN-b and OPN-c, lack exon-5
or exon-4, respectively [5]. All OPN mRNAs contain exon-2, which acts as the signal sequence.
The OPN-FL/OPN-a mRNA can be translated into two functionally distinct isoforms, secreted OPN-a
(sOPN) and intracellular OPN-a (iOPN), respectively. Both OPN-FL isoforms are generated from two
alternative translation initiation sites, the start codon, adenine uracil guanine (AUG) site with the
signal sequence or an alternate non-AUG site without the signal sequence [5]. The AUG site initiates
translation to produce OPN-a (sOPN) isoform consisting of an N-terminal signal sequence allowing it
to be secreted outside the cell and functioning as a pleiotropic cytokine [5]. The alternative non-AUG
site initiates translation to generate OPN-a (iOPN), which remains in the cytoplasm, premembrane
region and nucleus of DCs [18–23]. OPN-b mRNA and OPN-c mRNA produce the other two isoforms
of sOPNs (OPN-b and OPN-c, respectively) and are translated from their mRNAs and secreted out
from the cytoplasm [5].
OPN-a contains 314 amino acid (aa) residues, including a hydrophobic leader signal sequence of
16 aa [2]. OPN-a has one arginine–glycine–aspartic acid domain (RGD) with a cryptic sequence revealed
upon cleavage by thrombin [24]. OPN also has several binding sites for integrins, CD44, calcium and
heparin [5]. The RGD binding site is flanked by a 50-aa sequence, which is critical for binding to cell
surface integrins to regulate cell attachment, spreading, migration and intracellular signaling [25].
The OPN-a (iOPN) interacts with interferon regulatory factor-7 (IRF-7) and induces IFNα expression
in plasmacytoid dendritic cells (pDC) and promotes differentiation of IL-17 producing T helper cells
(Th-17 cells) in conventional dendritic cells (cDC) [20,26,27]. OPN-a (iOPN) has also been shown
to play a critical role in cell migration, fusion and motility. OPN-a (iOPN) can be colocalized with
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CD44 complex in cell processes, such as filopodia and pseudopodia, mediating cell migration through
cytoskeletal rearrangement in fibroblastic cells and osteoclasts [28,29]. OPN-a (iOPN) is also involved
in mitosis and progression of the cell cycle by influencing polo-like kinase-1 [23]. In Alzheimer’s
disease, OPN-a (iOPN) is found to be involved in abnormal β-amyloid protein aggregates [23,30].Vaccines 2020, 8, x 3 of 12 
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Figure 2. The generation of the different isoforms of OPN. The transcription of OPN genomic DNA
produces three different splice variants of OPN mRNA, i.e., OPN-a mRNA, OPN-b mRNA and OPN-c
mRNA. OPN-a mRNA contains all of the seven exons, whereas OPN-b mRNA and OPN-c mRNA
lack exon-5 and exon-4, respectively. During the translation process in the cytoplasm, OPN-a mRNA
produces two distinct isoforms, OPN-a (sOPN) and OPN-a (iOPN) through the AUG or non-AUG
translation sites, respectively. The AUG initiates translation to produce OPN-a (sOPN), which is
further modified in the endoplasmic reticulum and the Golgi complex and secreted outside the cell.
The alternative non-AUG site initiates translation to generate OPN-a (iOPN), which remains inside
the cell. OPN-b mRNA and OPN-c mRNA produce OPN-b and OPN-c that are secreted out from the
cytoplas . The figure was created in Bior nder.com.
1.3. The Function of Special Forms of OPN
Functional diversity of OPN is usually regulated by several post translational modifications
(PTMs), such as polymerization, matrix metalloproteinase (MMP) modification, thrombotic cleavag ,
phosphorylation, o-glycos lation, proteolytic proces ing and tyrosine sulfation and sialylation [31–33].
Here, we briefly discuss some commo PTMs, such s polymerization and thrombotic cleavage.
1.3.1. Polymerized OPN
OPN can be polymerized to form poly OPN by enzyme transglutaminase-2 (TG-2) [34]. TG-2
is a Ca2+-dependent protein cross-li king enzyme that catalyzes the formation of a covalent,
γ-glutamyl-ε-lysyl (iso eptide) bond between specific Lys a d Gln residues of its substrate
proteins [35,36]. It is not yet clear if all of the OPN isoforms can un ergo polymerization. However,
the presence of poly OPN has been confirmed in bone [37] and aortic tissue of matrix Gla protein-null
mice [38]. OPN acts as a chemotactic factor for neutrophils, lymphocytes and macrophages [39].
Vaccines 2020, 8, 748 4 of 12
The polymerized OPN acquires some functional modifications including the increased chemotactic
ability for neutrophils by binding with integrinα9β1 both in vivo and in vitro [40]. OPN polymerization
in vivo is dynamically regulated and could contribute to the regulation of tissue inflammation.
The increased number of TG-2 at the site of inflammation could lead to a rapid polymerization of OPN,
resulting in an increased level of neutrophils in the inflammatory site [40].
1.3.2. Thrombin-Cleaved OPN
OPN can be functionally and post translationally modified by thrombin cleavage. Two conserved
thrombin cleavage sites have been identified in human OPN (Figure 3). The major thrombin cleavage
site, termed Site-1, produces an N-terminal fragment containing the RGD domain termed OPN-N1
and a C-terminal fragment termed OPN-C1. The Site-2 cleavage exposes a cryptic site named the
SVVYGLR (arginine–valine–valine–tyrosine–glycine–leucine–arginine) domain located within the
RGD domain. Thrombin cleaves OPN at Site-2 and produces another distinct N-terminal fragment
termed OPN-N2 containing the SVVYGLR domain and C-terminal fragment termed OPN-C2.
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Figure 3. Generation of OPN fragments by thrombin cleavage. OPN can be post translationally
modified by thrombin cleavage. Two conserved thrombin cleavage sites have been identified in human
OPN. The major site, Site-1 cleavage, produces an N-terminal fragment containing the RGD domain
OPN-N1, and a C-terminal fragment OPN-C1. The Site-2 cleavage exposes a cryptic site, the SVVYGLR
domain located within the RGD domain. The Site-2 cleavage produces N-terminal fragment, OPN-N2
containing the SVVYGLR domain and C-terminal fragment, OPN-C2. The figure was created in
Biorender.com.
OPN-C1 and OPN-C2 exert an effect on cell–cell adhesion by interacting with CD44 isoforms
containing v6 and v7 domains and inhibit apoptosis [12]. Compared to C-terminal fragments,
N-terminal fragments show more biological activity due to the presence of the RGD and cryptic
SVVYGLR domains [12,41]. The RGD domain of OPN-N1 can bind to integrins αvβ1, αvβ3, αvβ5,
αvβ6, α5β1 and α8β1 [12,13]. In contrast, the cryptic SVVYGLR domain of OPN-N2 acts as the
ligand for integrins α4β1, α4β7, α9β1 and α9β4 to mediate cellular adhesion [13,25,42–44] (Figure 3).
As α4β1 integrin is expressed on lymphocytes and smooth muscle cells, integrin α4β1 and SVVYGLR
domain of OPN-N2 interaction may be involved in lymphocyte transmigration to the brain [12,13,44].
The SVVYGLR domain of OPN-N2 can also mediate neutrophil migration through binding with α4β1
integrin [45].
Vaccines 2020, 8, 748 5 of 12
2. Roles of OPN in the Pathogenesis of WNV
2.1. West Nile Virus
WNV is a single-stranded, positive-sensed, mosquito-transmitted RNA virus belonging to the
family of Flaviviridae. WNV infection in humans is asymptomatic in the majority of individuals;
however, in some cases, it can cause symptoms ranging from fever to neurological complications,
such as meningitis, encephalitis, flaccid paralysis and even death. WNV was first discovered in
Africa and first transmitted in the western world in 1999. WNV is now causing the most cases of
mosquito-borne encephalitis in North America [46].
2.2. OPN and WNV
The OPN-FL protein plays various roles in the pathogenesis of WNV encephalitis, such as
promoting inflammation [47], decreasing apoptosis of the infected cells [48] and promoting viral entry
into the brain [47]. It has been reported that OPN-N2 may contribute to lymphocyte and neutrophil
migration into the brain and decrease type I IFN signaling [12,13,44], whereas OPN-C1 and OPN-C2
decrease apoptosis of the virus-infected leukocytes and other host cells [12]. The blood–brain barrier
(BBB), composed of endothelial cell tight junctions and astrocyte extensions, protects the brain against
various insults including WNV and other neuroinvasive pathogens. Brain endothelial tight junctions
consist of integral membrane proteins (5ccluding, claudins and junctional adhesion molecules) that are
involved in intercellular contacts and interactions with cytoplasmic scaffolding proteins, such as zonula
occludens (Zo) proteins (Zo-1 and Zo-2), actin cytoskeleton and associated proteins [49,50]. WNV may
enter into the brain through multiple pathways, i.e., the direct crossing of the BBB, infection of the
endothelial cells of the BBB, infection of olfactory neurons, using the infected leukocytes as transporters
and axonal retrograde transport [47,51–54] (Figure 4). WNV infection induces the expression of many
host factors, some of which may directly or indirectly increase the permeability of the BBB, allowing
the virus to penetrate to the CNS. MMPs, such as MMP-2 and MMP-9, are found to be potent catalyzers
to breach the integrity of the BBB and enhance leukocyte infiltration into the CNS [54–57]. Brilha et al.
have shown that increased MMP-9 activity disrupts the tight junction of the BBB and decreases
expression of the tight junction proteins in a coculture model of the BBB [58]. MMP-9 activity is also
regulated by an endogenous tissue inhibitor of metalloproteinase-1 (TIMP-1), which preserves the BBB
integrity by inhibiting the enzymatic activity of MMP-9 [59].
Data from an animal study based on MMP-9 knockout (Mmp-9-/-) mice showed that MMP-9
mediated WNV entry into the CNS by increasing permeability of the BBB. In Mmp-9-/- mice, the levels
of viral load, inflammatory cytokines and leukocyte numbers were significantly lower than in the
wild-type (WT) control group. Moreover, Mmp-9-/- mice had a higher survival rate following a lethal
WNV infection with a tighter permeability of the BBB [54]. OPN has been shown to play a crucial
role in MMP-9 activation in melanoma growth and lung metastasis through nuclear factor kappa B
inducing kinase or mitogen-activated protein kinase kinase-1-dependent manner [60]. MMP-9 can
also increase the biological activities of OPN through PTM. Lindsey et al. showed that OPN could be
proteolytically cleaved by MMP-9 in at least 30 sites, and some of the cleaved fragments of OPN could
increase cardiac fibroblast migration after post myocardial infarction [61]. Therefore, it is possible that
OPN and MMP-9 interaction may facilitate WNV neuroinvasion by disrupting the BBB, which needs
further investigation. Previous studies also suggested that OPN is a neuroprotective mediator in
traumatic brain injury [62], stroke [63,64] and subarachnoid hemorrhage [65]. Shin et al. showed that
in a rat model of experimental autoimmune encephalomyelitis, OPN acted as both a proinflammatory
and neuroprotective mediator [66]. The roles of OPN depend on its cellular localization and the
stages of the disease course. In the acute stage of the disease, sOPN acts as a chemotactic factor
for immune cell migration and is involved in the generation of T helper-1 (Th-1) and Th-17 cells.
The iOPN may be involved in the cell survival signaling for recovery in the later stage of disease
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progression [66]. In addition, other mediators such as MMP-9 may also impact the roles of OPN during
the neuroinflammatory stage.
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Figure 4. Roles of OPN and MMP-9 in the West Nile virus (WNV) CNS entry. WNV infection
induces MMP-9 and OPN expression. MP-9 stimulates th activity of OPN by PTM cleavage and
OPN also stimulates MMP-9 activities. Both OPN and MMP-9 increase the permeability of the BBB
during WNV infection. MP-9 increases the permeability of BBB directly or by inhibiting Zo-1, while
TIMP-1 can inhibit MMP-9 activities on the BBB. The increa e of the permeability of the BBB facilitates
WNV particles to enter into the brain directly crossing the BBB or via neutrophil or other immune
cell-mediated “Trojan horse” transportation. Here, OPN increases neutrophil chemotaxis to the site of
neuroinflammation. The figure was created in Biorender.com.
Researchers from our lab and others have demonstrated that WNV infection increases OPN
production in both human and mouse cell culture, blood and brain tissues [47,48]. Importantly,
sOPN was also increased in the plasma of the patients during the acute phase of WNV infection and
remained at higher levels even after a few years of the recovery, compared to the healthy controls
(The Bai Lab unpublished data). To study the possible roles of OPN in the neuroinvasion of WNV,
OPN knockout (Opn-/-) mice were infected with a WT WNV strain (CT2741) via intraperitoneal (i.p.)
injection. The Opn-/- mice displayed relative resistance compared to the WT control (survival rate of 70%
vs. 30%), indicating OPN facilitated WNV infection in mice [47]. In one of our earlier studies, we found
both human and mouse neutrophils were very susceptible to WNV infection and may serve as carriers
for WNV dissemination in the peripheral tissues and the CNS [67]. Followed by WNV infection, Opn-/-
mice had a much tighter permeability of the BBB, less infiltration of WNV-infected neutrophils and
lower viral burden in the brain [47]. Moreover, recombinant OPN treatment significantly increased the
infiltration of WNV-infected polymorphonuclear neutrophils (PMNs) into the brain, and the mortality
rate of Opn-/- mice following WNV infection [47]. These results suggest that OPN facilitates WNV
neuroinvasion by recruiting WNV-infected PMNs into the brain [47]. However, when the viruses were
directly injected into the mouse brain bypassing the BBB, Opn-/- mice produced a slightly higher viral
load in the brain on day 6 post infection (p.i.) than the WT controls, suggesting OPN may also have a
protective role in the brain against WNV infection [47]. In contrast, another study showed an opposite
phenotype of Opn-/- mice followed by the infection with a mutant strain of WNV (Eg101), which is less
neuroinvasive than WT strains due to the lack of an envelope (E) protein glycosylation site [48,68].
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After a high dose (107 plaque-forming units) of the Eg101 challenge, Opn-/- mice presented higher
mortality compared to WT mice. In the early time points of the infection, OPN expression was suggested
to protect against the viral spread in the CNS by negatively controlling the type I IFN-sensitive, Caspase
1-dependent inflammasome, while promoting an alternative Caspase 8-associated pathway to control
the apoptosis of infected cells during WNV Eg101 infection in the CNS [48]. Successful replication of a
virus relies on the ability to block or delay apoptosis until sufficient progeny have been produced [69].
OPN has been reported to provide the antiapoptotic signal through binding to αvβ3 [70] and CD44
variants v6 and/or v7 [15,71–73]. Thus, it is possible that OPN signaling may help to bypass apoptosis
and thereby favor the spread of WNV infection in the CNS. However, this phenotype may also be
related to the specific strain of the virus and the overwhelming high dose resulting in the detection of
the viruses in the brain as early as day 1 p.i. in both WT and Opn-/- mice. More studies are needed to
dissect the detailed mechanisms of OPN in the pathogenesis of WNV.
In addition to the acute damages of the CNS, WNV infection has been suggested as a leading
factor to cause postinfectious CNS symptoms in patients. The postinfectious CNS symptoms include
the proinflammatory state that may contribute to long-term neuroinflammation and autoimmune
diseases in WNV survivors [46]. Clinical studies found that some WNV patients developed
autoimmune-related diseases, including Myasthenia gravis [74–76], Guillain–Barre syndrome
(GBS) [77], stiff-person syndrome [78], demyelinating neuropathies [79], brachial plexopathy [80] and
poliomyelitis syndrome [79], suggesting that WNV infection may promote or amplify underlying
autoimmunity. The postinfectious CNS symptoms are developed due to chronic elevation of various
cytokines following recovery from acute illness [46], and OPN is one of these cytokines [81]. OPN has
been shown to play critical roles in inducing autoimmune diseases, such as MS, GBS, multiple sclerosis
(MS), systemic lupus erythematosus, psoriasis and Sjogren syndrome [82–86]. It could mediate
autoimmune diseases through several mechanisms, such as increasing the level of Th-1 and Th-17 cells,
dysregulating follicular B cell activation, generating self-reactive autoantibodies, inhibiting apoptosis
of autoreactive cells and recruiting leukocytes to the site of inflammation [77]. MG is a long-term
neuromuscular disease that leads to varying degrees of skeletal muscle weakness due to autoantibodies
that block or destroy nicotinic acetylcholine receptors at the junction between the α-motor neuron and
muscle [83,87]. Elevation of OPN during and even after WNV infection may promote the production
of autoantibodies that lead to MG. GBS is an immune-mediated demyelinating disease of peripheral
nerves, and some patients developed GBS weeks after WNV infection [79]. The concentration of OPN
increased in cerebrospinal fluid of GBS patients, which was closely associated with the severity of
inflammation of the spinal cord [77]. However, further studies are warranted to determine the roles of
OPN in MG and GBS following WNV infection.
3. Concluding Remarks
OPN as a functionally diverse molecule has recently received a lot of attention due to its
critical roles in tumor progression, inflammation and microbial infections. Despite intensive studies,
the detailed roles of OPN are still not well understood. It is partly due to its variety of isoforms,
such as OPN-a (sOPN and iOPN), OPN-b, OPN-c and thrombin-cleaved fragments such as OPN-N1
(containing RGD domain), OPN-C1, OPN-N2 (containing SVVYGLR domain) and OPN-C2. The OPN
isoforms and fragments may coexist in the same microenvironment and exert different physiological
functions, making the investigations of OPN very complicated. In conclusion, OPN plays essential
roles in inflammation, wound healing, bone remodeling, tissue debridement, WNV encephalitis and
postinfectious CNS symptoms in WNV patients, yet more detailed research is warranted to determine
if OPN can be a clinical target for immunotherapeutic interventions.
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